Cleveland Clinic researchers cover the gamut when it comes to prostate cancer investigation, from elucidating mechanisms behind resistance to therapy to developing more precise diagnostics.
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies.
Researchers Discover Similarities in Next-Generation Prostate Cancer Drugs
Cleveland Clinic research findings suggest that effective steroidal antiandrogens share common metabolic activities and metabolites should be closely examined for effects on tumor survival.
A Path to Reverse Enzalutamide Resistance in Advanced Prostate Cancer
Cleveland Clinic researchers have outlined how resistance to enzalutamide treatment develops in advanced prostate cancer, and now have evidence about how to reverse it.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Androgen-Enhancing Gene Mutation Reduces Prostate Cancer Survival
Prostate cancer patients with an inherited gene mutation that enables intratumoral androgen synthesis are highly likely to develop resistance to androgen deprivation therapy and to die years earlier of their disease, researchers from Cleveland Clinic and Mayo Clinic have found. A screening test based on the mutation could inform clinical care.
Altering Abiraterone Metabolism Improves Anti-Tumor Effects in Aggressive Prostate Cancer
Pairing abiraterone with the enzyme inhibitor dutasteride modifies abiraterone’s metabolic conversion, blocking production of a prostate tumor-promoting metabolite while aiding accumulation of another metabolite that has strong anti-tumor effects, Cleveland Clinic researchers report.
Metabolite of Abiraterone Shows Efficacy Against Castration-Resistant Prostate Cancer
A novel metabolite of an approved agent for metastatic prostate cancer, Δ4-abiraterone, may be more effective than the parent drug, abiraterone, Cleveland Clinic researchers have found. They now will examine how D4A may prolong survival.
Cleveland Clinic’s Nima Sharifi, MD, Earns Prostate Cancer Foundation Challenge Awards
Cleveland Clinic medical oncologist Nima Sharifi, MD, is a recipient of two of the six 2015 Challenge Awards presented by the Prostate Cancer Foundation. Dr. Sharifi’s research focuses on metabolic and molecular mechanisms of resistance to hormonal therapy in prostate cancer.